Drug Type Small molecule drug |
Synonyms JTE 607 |
Target |
Action inhibitors |
Mechanism CPSF3 inhibitors(cleavage and polyadenylation specific factor 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC25H33Cl4N3O5 |
InChIKeyJUJAUEQJEWIWCQ-FJSYBICCSA-N |
CAS Registry188791-09-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Systemic Inflammatory Response Syndrome | Phase 2 | Japan | - | |
Systemic Inflammatory Response Syndrome | Phase 2 | - | - | |
Glioblastoma | Preclinical | China | 19 Mar 2024 | |
Glioblastoma | Preclinical | China | 19 Mar 2024 |